



0 049 605
A1

EUROPEAN PATENT APPLICATION

Ⓢ Int. Cl.³: **C 07 D 217/26**
C 07 C 103/52, A 61 K 31/47

②② Date of filing: 01.10.81


⑦1 Applicant: **WARNER-LAMBERT COMPANY**
201 Tabor Road
Morris Plains New Jersey 07950(US)

(72) Inventor: Hoeffle, Milton Louis
2108 Brockman Boulevard
Ann Arbor Michigan 48104(US)

(72) Inventor: Klutchko, Sylvester
5143 Pratt Road
Ann Arbor Michigan 48103(US)

**74 Representative: Jones, Michael Raymond et al,
Haseltine Lake & Co. 28 Southampton Buildings
Chancery Lane
London WC2A 1AT(GB)**

(57) There are disclosed substituted acyl derivatives of carbon atoms in a straight chain or branched chain; or a 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids having the following general formula:- CONR a pharmaceutically acceptable salt of the compound of formula I.



where R is a hydrogen atom or a lower alkyl or aralkyl radical; R¹ is a hydrogen atom or a lower alkyl or benzyl radical; R² is a hydrogen atom or a lower alkyl radical; Ar is a phenyl radical or a substituted phenyl radical having 1 or 2 substituents selected from fluorine, chlorine and bromine atoms and lower alkyl, lower alkoxy, hydroxy or amino radicals; X and Y are independently hydrogen atoms or lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphanyl, lower alkylsulphonyl or hydroxy radicals, or X and Y together constitute methylenedioxy; m is 0,1,2 or 3; and lower alkyl and lower alkoxy radicals contain from 1 to 4

The substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids and the pharmaceutically acceptable salts thereof may be produced by coupling a suitably substituted 1,2,3,4-tetrahydroisoquinoline with a suitably substituted amino acid and, when desired, hydrolysing or removing the protecting groups of the resulting product. The compounds of the invention, their salts and pharmaceutical compositions thereof are useful as antihypertensive agents.

EP 0 049 605 A1

USPN: 10/806,707 Filed: 3/23/2004 Art Unit: 1625
Docket: PC25242A Inventor: Jennings, et al.


-1-

SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-
TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACIDS, SALTS
THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING
THE DERIVATIVES OR SALTS, AND THE PRODUCTION OF
5 THE SAME

This invention relates to substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid compounds, salts thereof, pharmaceutical compositions containing the derivatives or salts, and
10 the production of the same.

One aspect of the present invention provides substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid compounds having the following general formula:

15



20

(I)

25

-2-


where R is a hydrogen atom or a lower alkyl or
 aralkyl radical; R¹ is a hydrogen atom or a lower alkyl
 or benzyl radical; R² is a hydrogen atom or a lower
 alkyl radical; Ar is a phenyl radical or a phenyl radical
 5 substituted with 1 or 2 substituents selected from
 fluorine, chlorine and bromine atoms and lower alkyl,
 lower alkoxy, hydroxy and amino radicals; X and Y are
 independently hydrogen atoms or lower alkyl, lower
 alkoxy, lower alkylthio, lower alkylsulphinyl, lower
 10 alkylsulphonyl or hydroxy radicals, or X and Y together
 constitute methylenedioxy; and m is 0,1,2 or 3; and the
 pharmaceutically acceptable acid salts thereof.

The terms "lower alkyl" and "lower alkoxy" as used
 herein are intended to mean an alkyl or alkoxy group in
 15 which the alkyl is straight or branched and has from one
 to four carbon atoms.

A preferred group of compounds of the present invention
 are acylated 1,2,3,4-tetrahydroisoquinoline-3-carboxylic
 acids having the following general formula:

20


25



where X and Y are as defined above, R¹ is hydrogen atom
 30 or an alkyl radical containing 1 to 3 carbon atoms, R²
 is a hydrogen atom or an alkyl radical containing 1 to 3
 carbon atoms, and Ar is a phenyl radical or a phenyl
 radical substituted in the para position by a fluorine,
 chlorine, bromine, methyl, hydroxy, methoxy or amino
 35 group; and pharmaceutically acceptable acid salts thereof.


Another preferred group of compounds of the present
 invention are those having the following general formula:

-3-



10 where R is a hydrogen atom or a t-butyl or benzyl radical; R^1 is a hydrogen atom or a C_{1-4} lower alkyl radical; R^2 is a hydrogen atom or a methyl or ethyl radical; and X and Y are independently hydrogen atoms or C_{1-4} lower alkyl, hydroxy or C_{1-4} lower alkoxy groups; or a pharmaceutically acceptable salt thereof.

15 More preferred compounds of the present invention are acylated 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids having the following general formula:




30 where R^2 is a hydrogen atom or an alkyl radical containing from 1 to 3 carbon atoms, and X and Y are independently hydrogen atoms or lower alkoxy radicals, and pharmaceutically acceptable salts thereof.


Even more preferred compounds are those having the following general formula:

35

-4-



10 where R² is a hydrogen atom or a methyl or ethyl radical;
or a pharmaceutically acceptable salt thereof; and those
having the following general formula:



20 where R² is a hydrogen atom or a methyl or ethyl radical;
or a pharmaceutically acceptable salt thereof.

Especially preferred compounds are those designated
2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid;
25 2-[2-[(1-ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid;
2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid; and
30 2-[2-[(1-ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid; and pharmaceutically acceptable acid salts of these four compounds.

The compounds of the present invention of formula
35 I have asymmetric carbon atoms indicated by asterisks.
The 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid used
in the present invention has the L (S) configuration.

This configuration has been shown to be required for biological activity, and thus active compounds of the invention are derived from either L(-) or DL-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.

5 Optical and diastereo isomers arising from the chirality at the centres marked with an asterisk in formula I and racemates and mixtures thereof are within the scope of the present invention. The S configuration at these centres is preferred.

10 The compounds of the present invention may exist in anhydrous form as well as in solvated, including hydrated, forms. In general, the hydrated forms and the other solvated forms with pharmaceutically acceptable solvents are equivalent to the anhydrous or unsolvated form for
15 the purposes of the present invention.

 The compounds of the present invention of formula I may be prepared from 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid by first protecting the carboxylic acid group, preferably as an ester, e.g. with a lower alkyl, benzyl or trimethylsilyl group. The protected carboxylic
20 acid compound is coupled to an N-protected amino acid, e.g. glycine or L-alanine, protected on its nitrogen atom, conveniently with t-butoxycarbonyl or benzyloxycarbonyl. The coupling may be carried out by any of a variety of
25 standard peptide coupling techniques as disclosed, for example, in "The Peptides. Analysis, Synthesis, Biology, Vol. 1 Major Methods of Peptide Bond Formation, Part A", ed. E. Gross, J. Meierhofer, Academic Press N.Y. (1979). An especially useful method involves the use of a dehydrating
30 agent, such as dicyclohexylcarbodiimide alone or in the presence of a reagent forming a reactive ester, e.g. 1-hydroxy-benzotriazole, in a suitable aprotic solvent such as dimethylformamide, acetonitrile, tetrahydrofuran or a chlorinated hydrocarbon. This gives the intermediate
35 (N-protected-2-aminoacyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid esters. These may then be either partially or totally deblocked depending on the protecting groups chosen, using anhydrous acids, e.g. hydrochloric acid in

•

10

15

25

30

Fi... ————— 4

-7-

diastereoisomers which can be separated by standard methods of fractional crystallization or chromatography.

The compounds of the present invention form acid salts with various inorganic and organic acids which are also within the scope of the present invention. The pharmaceutically acceptable acid addition salts of the compounds of the present invention may be prepared by conventional reactions by reacting the free amino acid or amino ester form of the product with one or more equivalents of the appropriate acid providing the desired anion in a solvent or medium in which the salt is insoluble, or in water and removing the water by freeze drying. The salts of strong acids are preferred. As exemplary, but not limiting, of pharmaceutically acceptable acid salts are the salts of hydrochloric, hydrobromic, sulphuric, nitric, acetic, fumeric, malic, maleic and citric acids.

The action of the enzyme renin on angiotensinogen, a pseudoglobulin in blood plasma, produces the decapeptide angiotensin I. Angiotensin I is converted by angiotensin-converting enzyme (ACE) to the octapeptide angiotensin II. The latter is an active pressor substance which has been implicated as the causative agent in various forms of hypertension in various mammalian species, e.g. rats and dogs. The compounds of this invention intervene in the renin→ angiotensin I→angiotensin II sequence by inhibiting angiotensin I converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II, and therefore are useful in reducing or relieving hypertension. Thus by the administration of a composition containing one or a combination of compounds of formula I or pharmaceutically acceptable salts thereof, hypertension in the species of mammal suffering therefrom is alleviated. A single dose or preferably two to four divided daily doses provided on a basis of from 0.1 to 100 mg per kilogram of weight of patient per day, preferably from 1 to 50 mg per kilogram per day, is appropriate to reduce blood pressure. The substance is preferably admini-


stered orally, but parenteral routes such as subcutaneously, intramuscularly, intravenously or intraperitoneally can also be employed.

In vitro ACE Assay: Angiotensin-converting enzyme (ACE) inhibitory activity was determined by assaying guinea pig serum ACE in the presence and absence of the test compound. ACE from guinea pig serum and the test compounds were preincubated for 10 minutes before the addition of the labelled substrate ^3H -hippuryl-glycyl-glycine. After a 60 minute incubation of 37°C the reaction was stopped by the addition of 0.1N HCl. ACE cleaves the hippuryl-glycyl bond to form the dipeptide glycyl-glycine and ^3H -hippuric acid. The ^3H -hippuric acid was then extracted with ethyl acetate and the ACE of a given sample calculated as the amount of ^3H -hippuric acid generated.



TABLE

Acyl Derivatives of
1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids
(S,S,S configuration) and their In-Vitro
Angiotensin-Converting Enzyme Inhibitory Activity



R	R ²	X	Y	Optical Rotation [α] _D ²³	ACE I Activity (in vitro) IC ₅₀ Molar Conc.
H	Et	H	H	+10.9° (1.0% EtOH)†	8.3 × 10 ⁻⁹
H	Et	OCH ₃	OCH ₃	+31.6° (1.0% EtOH)†	5.6 × 10 ⁻⁹
H	H	H	H	+14.5° (1.0% MeOH)†	2.8 × 10 ⁻⁹
H	H	OCH ₃	OCH ₃	+37.8° (1.0% MeOH)†	3.4 × 10 ⁻⁹
PhCH ₂	Et	H	H	-11.7° (1.0% MeOH)‡	2.0 × 10 ⁻⁶
t-Bu	Et	H	H	+ 6.4° (2.0% MeOH)‡	3.2 × 10 ⁻⁶
PhCH ₂	Et	OCH ₃	OCH ₃	+ 3.4° (1.0% EtOH)‡	3.0 × 10 ⁻⁷

† Hydrochloride Salt

‡ Maleate Salt

The compounds of the invention can be utilized to achieve the reduction of blood pressure by formulating in compositions such as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration. About 10 to 500 mg of a compound or mixture of compounds of formula I or physiologically acceptable salt thereof is compounded with a physiologically acceptable vehicle, carrier, excipient binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.

Illustrative of the adjuvants which may be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection, a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or a

synthetic fatty vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like can be incorporated as required.

The invention is illustrated by the following examples.

EXAMPLE 1

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid, Hydrochloride, Hydrate (S,S,S).

A quantity of 0.0079 mole of the hydrochloride of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethyl ester (S,S,S) dissolved in 100 ml of tetrahydrofuran was catalytically debenzylated with hydrogen and 0.5 g of 20% Pd/carbon at low pressure. The catalyst was filtered off and the product was precipitated as a relatively nonhydroscopic solid by the addition of a 10 fold quantity of ether; wt 3.7 g (88%); mp 120-140°C; tlc (20% MeOH-CHCl₃/SiO₂) one spot, Rf 0.5-0.7; [α]_D²³ = + 31.6° (1.05% EtOH).

Anal. Calc'd for C₂₇H₃₄N₂O₇·HCl·H₂O:

C, 58.63; H, 6.74; N, 5.07

Found: C, 58.59; H, 6.38; N, 5.06

The noncrystalline diester hydrochloride starting material used above was prepared by treatment of 5.54 g (0.0079 mole) of the maleate salt (prepared by the process of Example 5) with excess saturated sodium bicarbonate, extraction of the free base into 50% ether-ethyl acetate, treatment of this solution with excess hydrogen chloride and concentration at reduced pressure.

EXAMPLE 2

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid, Hydrochloride, Hydrate, (S,S,S).

Procedure A: Debenzylation procedure.

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate, (S,S,S) (prepared by the procedure of Example 6) was catalytically debenzylated by the procedure set forth in Example 1 to yield the product; mp 105-120°C; yield, 56%; tlc (20% MeOH-CHCl₃/ SiO₂) one spot R_F 0.5-0.6; [α]_D²³ = +10.9° (1.03% EtOH).

Anal. Calc'd for C₂₅H₃₀N₂O₅·HCl·H₂O:

C, 60.90; H, 6.75; N, 5.68

Found: C, 61.00; H, 6.37; N, 5.59

Procedure B: Via cleavage of 1,1-dimethylethyl ester.

A quantity of 100 g of trifluoroacetic acid was added to 11.6 g (0.023 mole) of 2-[2-[[1-ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 1,1-dimethylethyl ester (S,S,S) (prepared by the procedure of Example 7). The mixture was stirred to solution and for one hour at room temperature. Most of the trifluoroacetic acid was removed on the rotary evaporator and the remaining traces were removed by the successive additions and removal by rotary evaporation of 2 x 50 ml of THF. The residual oil was dissolved in about 400 ml of dry ether and the hydrochloride was precipitated by addition of a solution of 1.0 g (excess) of dry hydrogen chloride dissolved in 20 ml of dry ether. After filtration and washing with dry ether, the filter cake was dissolved in about 250 ml of water. This solution was filtered through celite and freeze-dried to obtain the product as a partial hydrate; 10.0 g (90%); mp 113-120°C.



Anal. Calc'd for $C_{25}H_{30}N_2O_5 \cdot HCl \cdot 3/4 H_2O$:

C, 61.55; H, 6.70; N, 5.74

Found: C, 61.51; H, 6.49; N, 5.70

EXAMPLE 3

2-[2-[(1-Carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid, Hydrochloride, Hydrate (S,S,S).

A solution of 0.553 g (0.001 mole) of 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) (prepared by the process of Example 1) in 4 ml (0.004 mole) of 1N sodium hydroxide and 4 ml of methanol was allowed to stand at room temperature for 20 hours. The reaction solution was added to 5 ml of 1N hydrochloric acid and concentrated at reduced pressure. The last amounts of water were removed by two successive additions and removal at reduced pressure of 25 ml portions of ethanol. The organic portion of the residue was dissolved in 0.5 ml of methanol. Chloroform (30 ml) was added and the solution was dried over sodium sulfate, charcoaled, filtered, and concentrated to give 0.45 g product. This amorphous material was dissolved in 20 ml of tetrahydrofuran and 100 ml of ether was added to precipitate a near white solid product; wt 0.4 g; mp 145-170°C; yield, 80%; tlc (20% MeOH-CHCl₃/SiO₂) R_f 0.1; $[\alpha]_{23} = +37.8^\circ$ (1.09% MeOH).

D

Anal. Calc'd for $C_{25}H_{30}N_2O_7 \cdot HCl \cdot H_2O$:

C, 57.19; H, 6.34; N, 5.34

Found: C, 57.17; H, 6.10; N, 5.51

EXAMPLE 4

2-[2-[(1-Carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isouquinolinecarboxylic Acid, Hydrochloride, Hemihydrate (S,S,S).

2-[2-[(1-(Ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isouquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) was treated by the procedure set forth in Example 3 to yield the product; mp 140-170°C; yield, 39%; $[\alpha]_{23} = +14.5^\circ$ (1.08% MeOH).
D

Anal. Calc'd for $C_{23}H_{26}N_2O_5 \cdot HCl \cdot 1/2 H_2O$:

C, 60.59; H, 5.97; N, 6.15; Cl, 7.77

Found: C, 60.68; H, 6.04; N, 5.89; Cl, 7.04

EXAMPLE 5

2-[2-[(1-(Ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isouquinolinecarboxylic Acid, Phenylmethyl Ester, Maleate (S,S,S).

A stirred solution of 5.0 g (0.0158 mole) of ethyl α -[(1-carboxyethyl)amino]benzenebutanoate hydrochloride (S,S) (prepared by the process of Example 8) in 200 ml of methylene chloride was treated successively with 1.60 g (0.0158 mole) of triethylamine, 2.14 g (0.0158 mole) of 1-hydroxybenzotriazole, 5.16 g (0.0158 mole) of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isouquinolinecarboxylic acid, phenylmethyl ester free base (S-form) (prepared by the process of Example 9); and then with 3.26 g (0.0158 mole) of dicyclohexylcarbodiimide in 10 ml of methylene dichloride. Dicyclohexylurea gradually separated. The mixture was allowed to stand at room temperature overnight. Hexane (300 ml) was added and the urea was filtered. The filtrate was washed with 250 ml of saturated sodium bicarbonate, dried over sodium sulfate and concentrated to remove solvent. The viscous residue was triturated with 50 ml of ether and filtered to remove insolubles. The filtrate was concentrated to give 9.2 g (99%) of crude base.

Preparation of maleate salt: A solution of 9.0 g (0.015 mole) of the above crude base in 50 ml of ethyl acetate was treated with a warm (40°C) solution of 1.86 g (0.016 mole) of maleic acid in 50 ml of ethyl acetate. White crystals separated; wt 7.2 g (65%); mp 139-141°C; tlc of base (generated with aq. sodium bicarbonate treatment of the salt and ethyl acetate extraction) showed one spot, R_f 0.7 (EtOAc/SiO₂). Recrystallization from ethyl acetate gave pure material of the same mp; [α]_D²³ = +3.4° (1.05% EtOH).

D

Anal. Calc'd for C₃₄H₄₀N₂O₇·C₄H₄O₄:

C, 64.74; H, 6.29; N, 3.98

Found: C, 64.48; H, 6.30; N, 3.99

EXAMPLE 6

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid, Phenylmethyl Ester, Maleate (S,S,S).

Ethyl α-[(1-carboxyethyl)amino]benzenebutanoate hydrochloride (S,S) (prepared by the process of Example 8) was coupled with 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, phenylmethyl ester free base (S-form) (prepared by the process of Example 10) by the same procedure used in Example 5; yield, 61%; mp 151-153°C (recrystallized from ethyl acetate); tlc of base showed one spot, R_f 0.8 (EtOAc/SiO₂); [α]_D²³ = -11.7° (1.0% MeOH).

D

Anal. Calc'd for C₃₂H₃₆N₂O₅·C₄H₄O₄:

C, 67.07; H, 6.25; N, 4.35

Found: C, 66.58; H, 6.09; N, 4.25

EXAMPLE 7

2-[2-[[1-Ethoxycarbonyl]-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid, 1,1-Dimethylethyl Ester (S,S,S).

A mixture of 8.38 g (0.03 mole) of ethyl α-[(1-carboxyethyl)amino]benzenebutanoate (free amino acid) (S,S) (prepared by the process of Example 8),

8.09 g (0.03 mole) of 1,2,3,4-tetrahydro-3-isoquinoline-carboxylic acid, 1,1-dimethylethyl ester hydrochloride (S-form) (prepared by the process of Example 11), 4.05 g (0.03 mole) of 1-hydroxybenzotriazole and 250 ml of THF was cooled in an ice bath to 3-5°C. With stirring, 3.04 g (0.03 mole) of triethylamine was added, then a solution of 6.92 g (0.0335 mole) of dicyclohexylcarbodiimide in 30 ml of THF was dropped in slowly over 20 minutes. The reaction mixture was stirred at 3-5°C for one hour. The ice bath was removed, and the reaction mixture stirred an additional 3 hours. The separated mixture of triethylamine hydrochloride and dicyclohexylurea was removed by filtration and washed with THF. The filtrate was evaporated on the rotary evaporation to remove all volatiles. The resulting gum was dissolved in about 300 ml of ethyl acetate. After filtration through celite the ethyl acetate solution was extracted 2 times with 100 ml of saturated sodium bicarbonate solution, once with 75 ml of 2N citric acid solution, once with 100 ml of saturated sodium bicarbonate solution and once with 100 ml of saturated sodium chloride solution. After drying with anhydrous MgSO_4 and filtration, the ethyl acetate was removed on the rotary evaporator to yield 16.9 g of a light brown gum. This gum was dissolved in 350 ml of boiling hexane and decanted through celite. The hexane solution was cooled in ice, seeded and stirred until crystallization was well established. The product was filtered, washed with cold hexane and dried; wt 11.6 g (78%); mp 68.5-71°C; $[\alpha]_{23}^D = -12.2^\circ$ (2% MeOH). Pure material had mp 71-72°C; $[\alpha]_{23}^D = -12.6^\circ$ (2% MeOH). The maleate salt had mp 127.5-128.5°C; $[\alpha]_{23}^D = +46.4$ (2% MeOH).

EXAMPLE 8

Ethyl α -[(1-Carboxyethyl)amino]benzenebutanoate Hydrochloride (S,S).

A solution of 2.0 g of t-butyl alanine (S-form) and 3.78 g of ethyl 2-bromo-4-phenylbutanoate in 25 ml of dimethylformamide was treated with 1.8 ml of triethylamine and the solution was heated at 70°C for 18 hours. The solvent was removed at reduced pressure and the residue was mixed with water and extracted with ethyl ether. The organic layer was washed with water and dried over magnesium sulfate. Concentration of the solvent at reduced pressure gave the oily t-butyl ester of the intermediate which was found to be sufficiently pure by gas liquid chromatography for further use.

A solution of 143.7 g of this t-butyl ester in 630 ml of trifluoroacetic acid was stirred at room temperature for one hour. The solvent was removed at reduced pressure and the residue was dissolved in ethyl ether and again evaporated. This operation was repeated. Then the ether solution was treated dropwise with a solution of hydrogen chloride gas in ethyl ether until precipitation ceased. The solid, collected by filtration, was a mixture of diastereoisomers, mp 153-165°C, $[\alpha]_{23} = +3.6^\circ$ (1% MeOH).

D

In order to separate the preferred S, S isomer, a suspension of 10.0 g of the mixture in 200 ml of methylene chloride was stirred at room temperature for five minutes and filtered; the solid was washed with additional methylene chloride and finally ether. The solid material, mp 202-208°C (dec.), $[\alpha]_{23} = -29.3^\circ$

D

(1% MeOH) was the less preferred diastereoisomer having the R, S configuration (S referring to the portion derived from L-alanine). The preferred S, S diastereoisomer was recovered from the filtrate after concentration and trituration of the residue with ether; mp 137-139°C; $[\alpha]_{23} = +31.3^\circ$ (1% MeOH).

D

The free amino acid (S,S-form) was prepared by treatment of an aqueous solution of the hydrochloride with saturated sodium acetate. The product was filtered, washed efficiently with cold water and recrystallized from ethyl acetate; mp 149-151°C; $[\alpha]_{23}^D = +29.7^\circ$

(1% 0.1N HCl).

EXAMPLE 9

1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinoline-carboxylic Acid, Phenylmethyl Ester, Hydrochloride (S-form).

A mixture of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride (S-form) and 600 ml of benzyl alcohol was saturated with hydrogen chloride gas. The temperature rose to 45°C. The mixture was stirred at room temperature for three days. A relatively small amount of solid was filtered off and the filtrate was treated with ca 2-liters of ether to precipitate crude product; wt 37.5 g; yield, 83%. Purification was effected by treatment with excess saturated sodium bicarbonate, extraction of base into ethyl acetate and precipitation of hydrochloride salt with HCl gas. Recrystallization from methanol-ether gave pure product; mp 255-260°C; $[\alpha]_{23}^D = -81.3^\circ$ (1.0%

MeOH); tlc (20% MeOH-CHCl₃/SiO₂) one spot Rf 0.8.

Anal. Calc'd for C₁₉H₂₁NO₄·HCl:

C, 62.72; H, 6.10; N, 3.85

Found: C, 62.54; H, 5.99; N, 4.00

EXAMPLE 10

1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic Acid, Phenylmethyl Ester, Hydrochloride (S-form).

Benzyl alcohol, 750 ml, was treated with 150 g of commercial polyphosphoric acid and warmed and stirred at 90°C to obtain a homogeneous mixture. Solid 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (S-form) 165.2 g was added. The mixture was stirred 4 hours at

95-105°C and then allowed to stand at room temperature for 18 hours. A solution of 18.5 g gaseous hydrochloric acid in 2.5 l of anhydrous ether was added, and the product separated slowly on cooling overnight. Filtration gave the crude benzyl 1,2,3,4-tetrahydro-3-isoquinoline carboxylate hydrochloride. This was purified by recrystallization from ethanol twice to give material with mp 190.5-191°C; $[\alpha]_{23}^D = -83.3^\circ$ (1% 1:1

methanol/1N hydrochloric acid).

EXAMPLE 11

1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic Acid, 1,1-Dimethylethyl Ester Hydrochloride (S-form).

This compound was prepared by passing 447 g of isobutylene into a 0°C solution of 63.5 g of 1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid (S-form) in 650 ml of dry dioxane and 65 ml of concentrated sulfuric acid under nitrogen. The reaction vessel was sealed and shaken for 17 hours at room temperature. The reaction vessel was vented and the mixture was poured into 25 l of cold 2N sodium hydroxide. The product is extracted into ether. The ether solution was washed with water, dried, and concentrated to about 500 ml. This was treated with excess 6N isopropanolic hydrochloric acid to precipitate the product, which was collected by filtration. A sample purified by recrystallization from ethanol/ether had mp 190-192°C (dec.), $[\alpha]_{23}^D =$

-88.7° (2% MeOH).

EXAMPLE 12

A quantity of 1000 tablets each containing 100 mg of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) is produced from the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]-amino]-1-oxopropyl]1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride hydrate (S,S,S)	100	g
Corn starch	50	g
Gelatin	7.5	g
Avicel (microcrystalline cellulose)	25	g
Magnesium stearate	2.5	g

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) and corn starch are admixed with an aqueous solution of the gelatin. The mixture is dried and ground to fine powder. The Avicel and then the magnesium stearate are admixed with the granulation. This is then compressed in a tablet press to form 1000 tablets each containing 100 mg of active ingredients.

EXAMPLE 13

A quantity of 1000 tablets each containing 200 mg of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) is produced from the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]-amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S)	200 g
Lactose	100 g
Avicel	150 g
Corn starch	50 g
Magnesium stearate	5 g

The 2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) lactose and Avicel are admixed, then blended with the corn starch. Magnesium stearate is added. The dry mixture is compressed in a tablet press to form 1000, 505 mg tablets each containing 200 mg of active ingredient. The tablets are coated with a solution of Methocel E 15 (methyl cellulose) including as a color a lake containing yellow No. 6.

EXAMPLE 14

Two piece No. 1 gelatin capsules each containing 250 mg of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) are filled with a mixture of the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]- amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7- dimethoxy-3-isquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S)	250 mg
Magnesium stearate	7 mg
USP lactose	193 mg

EXAMPLE 15


An injectable solution is produced as follows:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]- amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7- dimethoxy-3-isquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S)	500 g
Methyl paraben	5 g
Propyl paraben	1 g
Sodium chloride	25 g
Water for injection q.s.	5 l

The active substance, preservatives and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into presterilized vials which are then closed with presterilized rubber closures. Each vial contains 5 ml of solution in a concentration of 100 mg of active ingredient per ml of solution for injection.


CLAIMS for all designated States other than Austria:

1. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:



where R is a hydrogen atom or a lower alkyl or aralkyl radical; R^1 is a hydrogen atom or a lower alkyl or benzyl radical; R^2 is a hydrogen atom or a lower alkyl radical; Ar is a phenyl radical or a substituted phenyl radical having 1 or 2 substituents selected from fluorine, chlorine and bromine atoms and lower alkyl, lower alkoxy, hydroxy or amino radicals; X and Y are independently hydrogen atoms or lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphanyl, lower alkylsulphonyl or hydroxy radicals, or X and Y together constitute methylenedioxy; m is 0, 1, 2 or 3; and lower alkyl and lower alkoxy radicals contain from 1 to 4 carbon atoms in a straight chain or branched chain; or a pharmaceutically acceptable salt of the compound of formula I.


2. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to Claim 1 and having the following general formula:



-24-


where R is a hydrogen atom or a 1-butyl or benzyl radical; R¹ is a hydrogen atom or a C₁₋₄ lower alkyl radical; R² is a hydrogen atom or a methyl or ethyl radical; and X and Y are independently hydrogen atoms or C₁₋₄ lower alkyl, hydroxy or C₁₋₄ lower alkoxy groups; or a pharmaceutically acceptable salt thereof.

3. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to Claim 2 and having the following general formula:



where R² is a hydrogen atom or a methyl or ethyl radical; or a pharmaceutically acceptable salt thereof.

4. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to Claim 2 and having the following general formula:



where R² is a hydrogen atom or a methyl or ethyl radical; or a pharmaceutically acceptable salt thereof.

5. A compound according to Claim 2, which is 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate (S,S,S); or 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-

1,2,3,4-tetrahydro-3-isoquinoline-carboxylic acid, phenylmethyl ester, maleate (S,S,S).

6. The compound according to Claim 2, which is 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinoline-carboxylic acid, 1,1-dimethylethyl ester (S,S,S).

7. A compound according to Claim 3, which is 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinoline-carboxylic acid, hydrochloride, hydrate (S,S,S).

8. A compound according to Claim 3, which is 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinoline-carboxylic acid, hydrochloride (S,S,S).

9. A compound according to Claim 3, which is 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethyl-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).


10. A compound according to Claim 4, which is 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).

11. A compound according to Claim 4, which is 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride (S,S,S).


12. A compound according to Claim 4, which is 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hemihydrate (S,S,S).

13. A process for producing a substituted acyl derivative of 1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid according to formula I in Claim 1 or a pharmaceutically acceptable salt thereof, which process comprises peptide coupling a suitably substituted 1,2,3,4-tetrahydro-3-isoquinoline carboxylate of the following general formula:

-26-



with an N-substituted amino acid of the following general formula:




where R^1 , R^2 , Ar, X, Y, and m are as defined in Claim 1 and R^3 is a suitably blocked carboxylic acid group; and, when desired, removing the blocking moiety of the carboxylic acid group R^3 ; and, where appropriate, converting the product to a pharmaceutically acceptable salt thereof.


14. A pharmaceutical composition comprising a substituted acyl derivative of a 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to formula I in Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

CLAIMS for Austria alone:-

1. A process for producing a substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:-




where R is a hydrogen atom or a lower alkyl or aralkyl radical; R^1 is a hydrogen atom or a lower alkyl or benzyl radical; R^2 is a hydrogen atom or a lower alkyl radical; Ar is a phenyl radical or a substituted phenyl radical having 1 or 2 substituents selected from fluorine, chlorine and bromine atoms and lower alkyl, lower alkoxy, hydroxy and amino radicals; X and Y are independently hydrogen atoms or lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphanyl, lower alkylsulphonyl or hydroxy radicals, or X and Y together constitute methylenedioxy; and m is 0,1,2 or 3; wherein lower alkyl and lower alkoxy radicals contain from 1 to 4 carbon atoms in a straight chain or branched chain; or a pharmaceutically acceptable salt of the compound of formula I: which process comprises peptide coupling a suitably substituted 1,2,3,4-tetrahydro-3-isoquinoline carboxylate of the following general formula:-




-28-

with an N-substituted amino acid of the following general formula:-




where R^1 , R^2 , Ar, X, Y and m are as defined above and R^3 is a suitably blocked carboxylic acid group; and, when desired, removing the blocking moiety of the carboxylic acid group R^3 ; and where appropriate converting the product into a pharmaceutically acceptable salt thereof.

2. A process according to Claim 1 which is for producing a substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:-




where R is a hydrogen atom or a t-butyl or benzyl radical; R^1 is a hydrogen atom or a lower alkyl radical; R^2 is a hydrogen atom or a methyl or ethyl radical; and X and Y are independently hydrogen atoms or lower alkyl, hydroxy or lower alkoxy radicals; or a pharmaceutically acceptable salt thereof.

3. A process according to Claim 1 which is for producing a substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:-



where R^2 is a hydrogen atom or a methyl or ethyl radical; or a pharmaceutically acceptable salt thereof.

4. A process according to Claim 1 which is for producing a substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:-



where R^2 is a hydrogen atom or a methyl or ethyl radical; or a pharmaceutically acceptable salt thereof.

5. A process according to Claim 2 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate (S,S,S).

6. A process according to Claim 2 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate (S,S,S).

7. A process according to Claim 2 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 1,1-dimethylethyl ester, (S,S,S).

8. A process according to Claim 3 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).

9. A process according to Claim 3 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride (S,S,S).

10. A process according to Claim 3 which is for producing 2-[2-[1-(carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).

11. A process according to Claim 4 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).

12. A process according to Claim 4 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride (S,S,S).

13. A process according to Claim 4 which is for producing 2-[2-[1-(carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hemihydrate (S,S,S).

14. A process for producing a pharmaceutical composition comprising a substituted acyl derivative of a 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to formula I in Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; which process comprises incorporating the compound of Claim 1 in a suitable carrier.




European Patent
Office

EUROPEAN SEARCH REPORT

0049605

Application number

EP 81 30 4541

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	<u>FR - A - 2 448 533</u> (MORTON-NORWICH) * claims * ---	1-4, 14	C 07 D 217/26 C 07 C 103/52 A 61 K 31/47
	<u>EP - A - 0 012 845</u> (TANABE SEIYAKU Co. Ltd.) * pages 1-4 * ---	1, 2, 4, 14	
P	<u>FR - A - 2 456 733</u> (MORTON-NORWICH) * claims * ---	1-4, 14	
P	<u>EP - A - 0 018 104</u> (TAKEDA YAKUKIU KOGYO K.K.) * pages 1-4 * ---	1-4, 14	TECHNICAL FIELDS SEARCHED (Int. Cl. 7) C 07 D 217/26 C 07 C 103/52 A 61 K 31/47
P	<u>EP - A - 0 018 549</u> (TANABE SEIYAKU Co. Ltd.) * pages 1-4 * ---	1-4, 14	
P	<u>US - A - 4 251 444</u> (FREED et al.) * columns 1 and 2 * ---	1-4, 14	
P	<u>EP - A - 0 031 741</u> (SCIENCE UNION et Cie.) * claims * ---	1-4, 14	CATEGORY OF CITED DOCUMENTS X: particularly relevant A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: conflicting application D: document cited in the application L: citation for other reasons
P	<u>EP - A - 0 024 852</u> (AMERICAN HOME PROD. Co.) * page 2; claims * -----	1-4, 14	
 The present search report has been drawn up for all claims			&: member of the same patent family, corresponding document
Place of search		Date of completion of the search	Examiner
The Hague		08.12.1981	BRIGHENTI


```
#####
#      #      #      #      #
#      #      #      #      #
#      #      #      #      #
#      #      #      #      #
#      #      #      #      #
#      #      #      #      #
#####
```

Job : 2053
Date: 2004-08-23
Time: 10:50:14



0 049 605
A1

12

Int. Cl.³: C 07 D 217/26
C 07 C 103/52, A 61 K 31/47

②② Date of filing: 01.10.81


71 Applicant: **WARNER-LAMBERT COMPANY**
201 Tabor Road
Morris Plains New Jersey 07950(US)

(72) Inventor: Hoeffle, Milton Louis
2108 Brockman Boulevard
Ann Arbor Michigan 48104(US)

(72) Inventor: Klutchko, Sylvester
5143 Pratt Road
Ann Arbor Michigan 48103(US)

**(74) Representative: Jones, Michael Raymond et al,
Hasettine Lake & Co. 28 Southampton Buildings
Chancery Lane
London WC2A 1AT(GB)**

(57) There are disclosed substituted acyl derivatives of carbon atoms in a straight chain or branched chain; or a 1,2,3,4-tetrahydroisquinoline-3-carboxylic acids having the following general formula:- CONR a pharmaceutically acceptable salt of the compound of formula I.



where R is a hydrogen atom or a lower alkyl or aralkyl radical; R¹ is a hydrogen atom or a lower alkyl or benzyl radical; R² is a hydrogen atom or a lower alkyl radical; Ar is a phenyl radical or a substituted phenyl radical having 1 or 2 substituents selected from fluorine, chlorine and bromine atoms and lower alkyl, lower alkoxy, hydroxy or amino radicals; X and Y are independently hydrogen atoms or lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphanyl, lower alkylsulphonyl or hydroxy radicals, or X and Y together constitute methylenedioxy; m is 0,1,2 or 3; and lower alkyl and lower alkoxy radicals contain from 1 to 4

The substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids and the pharmaceutically acceptable salts thereof may be produced by coupling a suitably substituted 1,2,3,4-tetrahydroisoquinoline with a suitably substituted amino acid and, when desired, hydrolysing or removing the protecting groups of the resulting product. The compounds of the invention, their salts and pharmaceutical compositions thereof are useful as anti-hypertensive agents.


EP 0 049 605 A1

-1-

SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-
TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACIDS, SALTS
THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING
THE DERIVATIVES OR SALTS, AND THE PRODUCTION OF
THE SAME

This invention relates to substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid compounds, salts thereof, pharmaceutical compositions containing the derivatives or salts, and the production of the same.

One aspect of the present invention provides substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid compounds having the following general formula:



(I)

-2-


where R is a hydrogen atom or a lower alkyl or
 aralkyl radical; R¹ is a hydrogen atom or a lower alkyl
 or benzyl radical; R² is a hydrogen atom or a lower
 alkyl radical; Ar is a phenyl radical or a phenyl radical
 5 substituted with 1 or 2 substituents selected from
 fluorine, chlorine and bromine atoms and lower alkyl,
 lower alkoxy, hydroxy and amino radicals; X and Y are
 independently hydrogen atoms or lower alkyl, lower
 alkoxy, lower alkylthio, lower alkylsulphanyl, lower
 10 alkylsulphonyl or hydroxy radicals, or X and Y together
 constitute methylenedioxy; and m is 0,1,2 or 3; and the
 pharmaceutically acceptable acid salts thereof.

The terms "lower alkyl" and "lower alkoxy" as used
 herein are intended to mean an alkyl or alkoxy group in
 15 which the alkyl is straight or branched and has from one
 to four carbon atoms.

A preferred group of compounds of the present invention
 are acylated 1,2,3,4-tetrahydroisoquinoline-3-carboxylic
 acids having the following general formula:

20


25



where X and Y are as defined above, R¹ is hydrogen atom
 30 or an alkyl radical containing 1 to 3 carbon atoms, R²
 is a hydrogen atom or an alkyl radical containing 1 to 3
 carbon atoms, and Ar is a phenyl radical or a phenyl
 radical substituted in the para position by a fluorine,
 chlorine, bromine, methyl, hydroxy, methoxy or amino
 35 group; and pharmaceutically acceptable acid salts thereof.


Another preferred group of compounds of the present
 invention are those having the following general formula:

-3-



10 where R is a hydrogen atom or a t-butyl or benzyl radical; R¹ is a hydrogen atom or a C₁₋₄ lower alkyl radical; R² is a hydrogen atom or a methyl or ethyl radical; and X and Y are independently hydrogen atoms or C₁₋₄ lower alkyl, hydroxy or C₁₋₄ lower alkoxy groups; or a pharmaceutically acceptable salt thereof.

15 More preferred compounds of the present invention are acylated 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids having the following general formula:




30 where R² is a hydrogen atom or an alkyl radical containing from 1 to 3 carbon atoms, and X and Y are independently hydrogen atoms or lower alkoxy radicals, and pharmaceutically acceptable salts thereof.


Even more preferred compounds are those having the following general formula:

35

-4-



10 where R^2 is a hydrogen atom or a methyl or ethyl radical;
or a pharmaceutically acceptable salt thereof; and those
having the following general formula:



20 where R^2 is a hydrogen atom or a methyl or ethyl radical;
or a pharmaceutically acceptable salt thereof.

Especially preferred compounds are those designated
2-[2-[(d-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,-
3,4-tetrahydro-3-isoquinolinecarboxylic acid;
25 2-[2-[(k(ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-
1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid;
2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-
1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinoline-
carboxylic acid; and
30 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl)amino]-1-
oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-
isoquinolinecarboxylic acid; and pharmaceutically
acceptable acid salts of these four compounds.

The compounds of the present invention of formula
35 I have asymmetric carbon atoms indicated by asterisks.
The 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid used
in the present invention has the L (S) configuration.

This configuration has been shown to be required for biological activity, and thus active compounds of the invention are derived from either L(-) or DL-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.

5 Optical and diastereo isomers arising from the chirality at the centres marked with an asterisk in formula I and racemates and mixtures thereof are within the scope of the present invention. The S configuration at these centres is preferred.

10 The compounds of the present invention may exist in anhydrous form as well as in solvated, including hydrated, forms. In general, the hydrated forms and the other solvated forms with pharmaceutically acceptable solvents are equivalent to the anhydrous or unsolvated form for
15 the purposes of the present invention.

 The compounds of the present invention of formula I may be prepared from 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid by first protecting the carboxylic acid group, preferably as an ester, e.g. with a lower alkyl,
20 benzyl or trimethylsilyl group. The protected carboxylic acid compound is coupled to an N-protected amino acid, e.g. glycine or L-alanine, protected on its nitrogen atom, conveniently with t-butoxycarbonyl or benzyloxycarbonyl. The coupling may be carried out by any of a variety of
25 standard peptide coupling techniques as disclosed, for example, in "The Peptides. Analysis, Synthesis, Biology, Vol. 1 Major Methods of Peptide Bond Formation, Part A", ed. E. Gross, J. Meierhofer, Academic Press N.Y. (1979). An especially useful method involves the use of a dehydrating
30 agent, such as dicyclohexylcarbodiimide alone or in the presence of a reagent forming a reactive ester, e.g. 1-hydroxy-benzotriazole, in a suitable aprotic solvent such as dimethylformamide, acetonitrile, tetrahydrofuran or a chlorinated hydrocarbon. This gives the intermediate
35 (N-protected-2-aminoacyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid esters. These may then be either partially or totally deblocked depending on the protecting groups chosen, using anhydrous acids, e.g. hydrochloric acid in



•

10

15

25

30

14

diastereoisomers which can be separated by standard methods of fractional crystallization or chromatography.

The compounds of the present invention form acid salts with various inorganic and organic acids which are also within the scope of the present invention. The pharmaceutically acceptable acid addition salts of the compounds of the present invention may be prepared by conventional reactions by reacting the free amino acid or amino ester form of the product with one or more equivalents of the appropriate acid providing the desired anion in a solvent or medium in which the salt is insoluble, or in water and removing the water by freeze drying. The salts of strong acids are preferred. As exemplary, but not limiting, of pharmaceutically acceptable acid salts are the salts of hydrochloric, hydrobromic, sulphuric, nitric, acetic, fumeric, malic, maleic and citric acids.

The action of the enzyme renin on angiotensinogen, a pseudoglobulin in blood plasma, produces the decapeptide angiotensin I. Angiotensin I is converted by angiotensin-converting enzyme (ACE) to the octapeptide angiotensin II. The latter is an active pressor substance which has been implicated as the causative agent in various forms of hypertension in various mammalian species, e.g. rats and dogs. The compounds of this invention intervene in the renin→angiotensin I→angiotensin II sequence by inhibiting angiotensin I converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II, and therefore are useful in reducing or relieving hypertension. Thus by the administration of a composition containing one or a combination of compounds of formula I or pharmaceutically acceptable salts thereof, hypertension in the species of mammal suffering therefrom is alleviated. A single dose or preferably two to four divided daily doses provided on a basis of from 0.1 to 100 mg per kilogram of weight of patient per day, preferably from 1 to 50 mg per kilogram per day, is appropriate to reduce blood pressure. The substance is preferably admini-


stered orally, but parenteral routes such as subcutaneously, intramuscularly, intravenously or intraperitoneally can also be employed.

In vitro ACE Assay: Angiotensin-converting enzyme (ACE) inhibitory activity was determined by assaying guinea pig serum ACE in the presence and absence of the test compound. ACE from guinea pig serum and the test compounds were preincubated for 10 minutes before the addition of the labelled substrate ^3H -hippuryl-glycyl-glycine. After a 60 minute incubation of 37°C the reaction was stopped by the addition of 0.1N HCl. ACE cleaves the hippuryl-glycyl bond to form the dipeptide glycyl-glycine and ^3H -hippuric acid. The ^3H -hippuric acid was then extracted with ethyl acetate and the ACE of a given sample calculated as the amount of ^3H -hippuric acid generated.



TABLE

Acyl Derivatives of
1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids
(S,S,S configuration) and their In-Vitro
Angiotensin-Converting Enzyme Inhibitory Activity



R	R ²	X	Y	Optical Rotation [α] _D ²³	ACE I Activity (in vitro) IC ₅₀ Molar Conc.
H	Et	H	H	+10.9° (1.0% EtOH)†	8.3 x 10 ⁻⁹
H	Et	OCH ₃	OCH ₃	+31.6° (1.0% EtOH)†	5.6 x 10 ⁻⁹
H	H	H	H	+14.5° (1.0% MeOH)†	2.8 x 10 ⁻⁹
H	H	OCH ₃	OCH ₃	+37.8° (1.0% MeOH)†	3.4 x 10 ⁻⁹
PhCH ₂	Et	H	H	-11.7° (1.0% MeOH)‡	2.0 x 10 ⁻⁶
t-Bu	Et	H	H	+ 6.4° (2.0% MeOH)‡	3.2 x 10 ⁻⁶
PhCH ₂	Et	OCH ₃	OCH ₃	+ 3.4° (1.0% EtOH)‡	3.0 x 10 ⁻⁷

† Hydrochloride Salt

‡ Maleate Salt

The compounds of the invention can be utilized to achieve the reduction of blood pressure by formulating in compositions such as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration. About 10 to 500 mg of a compound or mixture of compounds of formula I or physiologically acceptable salt thereof is compounded with a physiologically acceptable vehicle, carrier, excipient binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.

Illustrative of the adjuvants which may be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as water for injection, a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or a

synthetic fatty vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like can be incorporated as required.

The invention is illustrated by the following examples.

EXAMPLE 1

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid, Hydrochloride, Hydrate (S,S,S).

A quantity of 0.0079 mole of the hydrochloride of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethyl ester (S,S,S) dissolved in 100 ml of tetrahydrofuran was catalytically debenzylated with hydrogen and 0.5 g of 20% Pd/carbon at low pressure. The catalyst was filtered off and the product was precipitated as a relatively nonhydroscopic solid by the addition of a 10 fold quantity of ether; wt 3.7 g (88%); mp 120-140°C; tlc (20% MeOH-CHCl₃/SiO₂) one spot, Rf 0.5-0.7; [α]_D²³ = + 31.6° (1.05% EtOH).

Anal. Calc'd for C₂₇H₃₄N₂O₇·HCl·H₂O:

C, 58.63; H, 6.74; N, 5.07

Found: C, 58.59; H, 6.38; N, 5.06

The noncrystalline diester hydrochloride starting material used above was prepared by treatment of 5.54 g (0.0079 mole) of the maleate salt (prepared by the process of Example 5) with excess saturated sodium bicarbonate, extraction of the free base into 50% ether-ethyl acetate, treatment of this solution with excess hydrogen chloride and concentration at reduced pressure.

EXAMPLE 2

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid, Hydrochloride, Hydrate, (S,S,S).

Procedure A: Debenzylation procedure.

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate, (S,S,S) (prepared by the procedure of Example 6) was catalytically debenzylated by the procedure set forth in Example 1 to yield the product; mp 105-120°C; yield, 56%; tlc (20% MeOH-CHCl₃/ SiO₂) one spot R_f 0.5-0.6; [α]_D²³ = +10.9° (1.03% EtOH).

Anal. Calc'd for C₂₅H₃₀N₂O₅·HCl·H₂O:

C, 60.90; H, 6.75; N, 5.68

Found: C, 61.00; H, 6.37; N, 5.59

Procedure B: Via cleavage of 1,1-dimethylethyl ester.

A quantity of 100 g of trifluoroacetic acid was added to 11.6 g (0.023 mole) of 2-[2-[[1-ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 1,1-dimethylethyl ester (S,S,S) (prepared by the procedure of Example 7). The mixture was stirred to solution and for one hour at room temperature. Most of the trifluoroacetic acid was removed on the rotary evaporator and the remaining traces were removed by the successive additions and removal by rotary evaporation of 2 x 50 ml of THF. The residual oil was dissolved in about 400 ml of dry ether and the hydrochloride was precipitated by addition of a solution of 1.0 g (excess) of dry hydrogen chloride dissolved in 20 ml of dry ether. After filtration and washing with dry ether, the filter cake was dissolved in about 250 ml of water. This solution was filtered through celite and freeze-dried to obtain the product as a partial hydrate; 10.0 g (90%); mp 113-120°C.



Anal. Calc'd for $C_{25}H_{30}N_2O_5 \cdot HCl \cdot 3/4 H_2O$:

C, 61.55; H, 6.70; N, 5.74

Found: C, 61.51; H, 6.49; N, 5.70

EXAMPLE 3

2-[2-[(1-Carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid, Hydrochloride, Hydrate (S,S,S).

A solution of 0.553 g (0.001 mole) of 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) (prepared by the process of Example 1) in 4 ml (0.004 mole) of 1N sodium hydroxide and 4 ml of methanol was allowed to stand at room temperature for 20 hours. The reaction solution was added to 5 ml of 1N hydrochloric acid and concentrated at reduced pressure. The last amounts of water were removed by two successive additions and removal at reduced pressure of 25 ml portions of ethanol. The organic portion of the residue was dissolved in 0.5 ml of methanol. Chloroform (30 ml) was added and the solution was dried over sodium sulfate, charcoaled, filtered, and concentrated to give 0.45 g product. This amorphous material was dissolved in 20 ml of tetrahydrofuran and 100 ml of ether was added to precipitate a near white solid product; wt 0.4 g; mp 145-170°C; yield, 80%; tlc (20% MeOH-CHCl₃/SiO₂) R_f 0.1; $[\alpha]_{23} = +37.8^\circ$ (1.09% MeOH).

D

Anal. Calc'd for $C_{25}H_{30}N_2O_7 \cdot HCl \cdot H_2O$:

C, 57.19; H, 6.34; N, 5.34

Found: C, 57.17; H, 6.10; N, 5.51

EXAMPLE 4

2-[2-[(1-Carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isouquinolinecarboxylic Acid, Hydrochloride, Hemihydrate (S,S,S).

2-[2-[(1-(Ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isouquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) was treated by the procedure set forth in Example 3 to yield the product; mp 140-170°C; yield, 39%; $[\alpha]_{23}^{25} = +14.5^{\circ}$ (1.08% MeOH).
D

Anal. Calc'd for $C_{23}H_{26}N_2O_5 \cdot HCl \cdot 1/2 H_2O$:

C, 60.59; H, 5.97; N, 6.15; Cl, 7.77

Found: C, 60.68; H, 6.04; N, 5.89; Cl, 7.04

EXAMPLE 5

2-[2-[(1-(Ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isouquinolinecarboxylic Acid, Phenylmethyl Ester, Maleate (S,S,S).

A stirred solution of 5.0 g (0.0158 mole) of ethyl α -[(1-carboxyethyl)amino]benzenebutanoate hydrochloride (S,S) (prepared by the process of Example 8) in 200 ml of methylene chloride was treated successively with 1.60 g (0.0158 mole) of triethylamine, 2.14 g (0.0158 mole) of 1-hydroxybenzotriazole, 5.16 g (0.0158 mole) of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isouquinolinecarboxylic acid, phenylmethyl ester free base (S-form) (prepared by the process of Example 9); and then with 3.26 g (0.0158 mole) of dicyclohexylcarbodiimide in 10 ml of methylene dichloride. Dicyclohexylurea gradually separated. The mixture was allowed to stand at room temperature overnight. Hexane (300 ml) was added and the urea was filtered. The filtrate was washed with 250 ml of saturated sodium bicarbonate, dried over sodium sulfate and concentrated to remove solvent. The viscous residue was triturated with 50 ml of ether and filtered to remove insolubles. The filtrate was concentrated to give 9.2 g (99%) of crude base.

Preparation of maleate salt: A solution of 9.0 g (0.015 mole) of the above crude base in 50 ml of ethyl acetate was treated with a warm (40°C) solution of 1.86 g (0.016 mole) of maleic acid in 50 ml of ethyl acetate. White crystals separated; wt 7.2 g (65%); mp 139-141°C; tlc of base (generated with aq. sodium bicarbonate treatment of the salt and ethyl acetate extraction) showed one spot, Rf 0.7 (EtOAc/SiO₂). Recrystallization from ethyl acetate gave pure material of the same mp; $[\alpha]_{23} = +3.4^\circ$ (1.05% EtOH).

D

Anal. Calc'd for C₃₄H₄₀N₂O₇·C₄H₄O₄:

C, 64.74; H, 6.29; N, 3.98

Found: C, 64.48; H, 6.30; N, 3.99

EXAMPLE 6

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid, Phenylmethyl Ester, Maleate (S,S,S).

Ethyl α-[(1-carboxyethyl)amino]benzenebutanoate hydrochloride (S,S) (prepared by the process of Example 8) was coupled with 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, phenylmethyl ester free base (S-form) (prepared by the process of Example 10) by the same procedure used in Example 5; yield, 61%; mp 151-153°C (recrystallized from ethyl acetate); tlc of base showed one spot, Rf 0.8 (EtOAc/SiO₂); $[\alpha]_{23} = -11.7^\circ$ (1.0% MeOH).

D

Anal. Calc'd for C₃₂H₃₆N₂O₅·C₄H₄O₄:

C, 67.07; H, 6.25; N, 4.35

Found: C, 66.58; H, 6.09; N, 4.25

EXAMPLE 7

2-[2-[[1-Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid, 1,1-Dimethylethyl Ester (S,S,S).

A mixture of 8.38 g (0.03 mole) of ethyl α-[(1-carboxyethyl)amino]benzenebutanoate (free amino acid) (S,S) (prepared by the process of Example 8),

8.09 g (0.03 mole) of 1,2,3,4-tetrahydro-3-isoquinoline-carboxylic acid, 1,1-dimethylethyl ester hydrochloride (S-form) (prepared by the process of Example 11), 4.05 g (0.03 mole) of 1-hydroxybenzotriazole and 250 ml of THF was cooled in an ice bath to 3-5°C. With stirring, 3.04 g (0.03 mole) of triethylamine was added, then a solution of 6.92 g (0.0335 mole) of dicyclohexylcarbodiimide in 30 ml of THF was dropped in slowly over 20 minutes. The reaction mixture was stirred at 3-5°C for one hour. The ice bath was removed, and the reaction mixture stirred an additional 3 hours. The separated mixture of triethylamine hydrochloride and dicyclohexylurea was removed by filtration and washed with THF. The filtrate was evaporated on the rotary evaporation to remove all volatiles. The resulting gum was dissolved in about 300 ml of ethyl acetate. After filtration through celite the ethyl acetate solution was extracted 2 times with 100 ml of saturated sodium bicarbonate solution, once with 75 ml of 2N citric acid solution, once with 100 ml of saturated sodium bicarbonate solution and once with 100 ml of saturated sodium chloride solution. After drying with anhydrous MgSO_4 and filtration, the ethyl acetate was removed on the rotary evaporator to yield 16.9 g of a light brown gum. This gum was dissolved in 350 ml of boiling hexane and decanted through celite. The hexane solution was cooled in ice, seeded and stirred until crystallization was well established. The product was filtered, washed with cold hexane and dried; wt 11.6 g (78%); mp 68.5-71°C; $[\alpha]_{23}^D = -12.2^\circ$ (2% MeOH). Pure material had mp 71-72°C; $[\alpha]_{23}^D = -12.6^\circ$ (2% MeOH). The maleate salt had mp 127.5-128.5°C; $[\alpha]_{23}^D = +46.4$ (2% MeOH).

EXAMPLE 8

Ethyl α -[(1-Carboxyethyl)amino]benzenebutanoate Hydrochloride (S,S).

A solution of 2.0 g of t-butyl alanine (S-form) and 3.78 g of ethyl 2-bromo-4-phenylbutanoate in 25 ml of dimethylformamide was treated with 1.8 ml of triethylamine and the solution was heated at 70°C for 18 hours. The solvent was removed at reduced pressure and the residue was mixed with water and extracted with ethyl ether. The organic layer was washed with water and dried over magnesium sulfate. Concentration of the solvent at reduced pressure gave the oily t-butyl ester of the intermediate which was found to be sufficiently pure by gas liquid chromatography for further use.

A solution of 143.7 g of this t-butyl ester in 630 ml of trifluoroacetic acid was stirred at room temperature for one hour. The solvent was removed at reduced pressure and the residue was dissolved in ethyl ether and again evaporated. This operation was repeated. Then the ether solution was treated dropwise with a solution of hydrogen chloride gas in ethyl ether until precipitation ceased. The solid, collected by filtration, was a mixture of diastereoisomers, mp 153-165°C, $[\alpha]_{23} = +3.6^\circ$ (1% MeOH).

D

In order to separate the preferred S, S isomer, a suspension of 10.0 g of the mixture in 200 ml of methylene chloride was stirred at room temperature for five minutes and filtered; the solid was washed with additional methylene chloride and finally ether. The solid material, mp 202-208°C (dec.), $[\alpha]_{23} = -29.3^\circ$

D

(1% MeOH) was the less preferred diastereoisomer having the R, S configuration (S referring to the portion derived from L-alanine). The preferred S, S diastereoisomer was recovered from the filtrate after concentration and trituration of the residue with ether; mp 137-139°C; $[\alpha]_{23} = +31.3^\circ$ (1% MeOH).

D

The free amino acid (S,S-form) was prepared by treatment of an aqueous solution of the hydrochloride with saturated sodium acetate. The product was filtered, washed efficiently with cold water and recrystallized from ethyl acetate; mp 149-151°C; $[\alpha]_{23}^D = +29.7^\circ$

(1% 0.1N HCl).

EXAMPLE 9

1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinoline-carboxylic Acid, Phenylmethyl Ester, Hydrochloride (S-form).

A mixture of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride (S-form) and 600 ml of benzyl alcohol was saturated with hydrogen chloride gas. The temperature rose to 45°C. The mixture was stirred at room temperature for three days. A relatively small amount of solid was filtered off and the filtrate was treated with ca 2-liters of ether to precipitate crude product; wt 37.5 g; yield, 83%. Purification was effected by treatment with excess saturated sodium bicarbonate, extraction of base into ethyl acetate and precipitation of hydrochloride salt with HCl gas. Recrystallization from methanol-ether gave pure product; mp 255-260°C; $[\alpha]_{23}^D = -81.3^\circ$ (1.0%

MeOH); tlc (20% MeOH-CHCl₃/SiO₂) one spot Rf 0.8.

Anal. Calc'd for C₁₉H₂₁NO₄·HCl:

C, 62.72; H, 6.10; N, 3.85

Found: C, 62.54; H, 5.99; N, 4.00

EXAMPLE 10

1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic Acid, Phenylmethyl Ester, Hydrochloride (S-form).

Benzyl alcohol, 750 ml, was treated with 150 g of commercial polyphosphoric acid and warmed and stirred at 90°C to obtain a homogeneous mixture. Solid 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (S-form) 165.2 g was added. The mixture was stirred 4 hours at

95-105°C and then allowed to stand at room temperature for 18 hours. A solution of 18.5 g gaseous hydrochloric acid in 2.5 l of anhydrous ether was added, and the product separated slowly on cooling overnight. Filtration gave the crude benzyl 1,2,3,4-tetrahydro-3-isoquinoline carboxylate hydrochloride. This was purified by recrystallization from ethanol twice to give material with mp 190.5-191°C; $[\alpha]_{23}^D = -83.3^\circ$ (1% 1:1

methanol/1N hydrochloric acid).

EXAMPLE 11

1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic Acid, 1,1-Dimethylethyl Ester Hydrochloride (S-form).

This compound was prepared by passing 447 g of isobutylene into a 0°C solution of 63.5 g of 1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid (S-form) in 650 ml of dry dioxane and 65 ml of concentrated sulfuric acid under nitrogen. The reaction vessel was sealed and shaken for 17 hours at room temperature. The reaction vessel was vented and the mixture was poured into 25 l of cold 2N sodium hydroxide. The product is extracted into ether. The ether solution was washed with water, dried, and concentrated to about 500 ml. This was treated with excess 6N isopropanolic hydrochloric acid to precipitate the product, which was collected by filtration. A sample purified by recrystallization from ethanol/ether had mp 190-192°C (dec.), $[\alpha]_{23}^D =$

-88.7° (2% MeOH).

EXAMPLE 12

A quantity of 1000 tablets each containing 100 mg of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) is produced from the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]-amino]-1-oxopropyl]1,2,3,4-Tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride hydrate (S,S,S)	100	g
Corn starch	50	g
Gelatin	7.5	g
Avicel (microcrystalline cellulose)	25	g
Magnesium stearate	2.5	g

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) and corn starch are admixed with an aqueous solution of the gelatin. The mixture is dried and ground to fine powder. The Avicel and then the magnesium stearate are admixed with the granulation. This is then compressed in a tablet press to form 1000 tablets each containing 100 mg of active ingredients.

EXAMPLE 13

A quantity of 1000 tablets each containing 200 mg of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) is produced from the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S)	200 g
Lactose	100 g
Avicel	150 g
Corn starch	50 g
Magnesium stearate	5 g

The 2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) lactose and Avicel are admixed, then blended with the corn starch. Magnesium stearate is added. The dry mixture is compressed in a tablet press to form 1000, 505 mg tablets each containing 200 mg of active ingredient. The tablets are coated with a solution of Methocel E 15 (methyl cellulose) including as a color a lake containing yellow No. 6.

EXAMPLE 14

Two piece No. 1 gelatin capsules each containing 250 mg of 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S) are filled with a mixture of the following ingredients:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]- amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7- dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S)	250 mg
Magnesium stearate	7 mg
USP lactose	193 mg

EXAMPLE 15


An injectable solution is produced as follows:

2-[2-[[1-(Ethoxycarbonyl)-3-phenylpropyl]- amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7- dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S)	500 g
Methyl paraben	5 g
Propyl paraben	1 g
Sodium chloride	25 g
Water for injection q.s.	5 l

The active substance, preservatives and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into presterilized vials which are then closed with presterilized rubber closures. Each vial contains 5 ml of solution in a concentration of 100 mg of active ingredient per ml of solution for injection.


CLAIMS for all designated States other than Austria:

1. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:



where R is a hydrogen atom or a lower alkyl or aralkyl radical; R^1 is a hydrogen atom or a lower alkyl or benzyl radical; R^2 is a hydrogen atom or a lower alkyl radical; Ar is a phenyl radical or a substituted phenyl radical having 1 or 2 substituents selected from fluorine, chlorine and bromine atoms and lower alkyl, lower alkoxy, hydroxy or amino radicals; X and Y are independently hydrogen atoms or lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphanyl, lower alkylsulphonyl or hydroxy radicals, or X and Y together constitute methylenedioxy; m is 0, 1, 2 or 3; and lower alkyl and lower alkoxy radicals contain from 1 to 4 carbon atoms in a straight chain or branched chain; or a pharmaceutically acceptable salt of the compound of formula I.


2. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to Claim 1 and having the following general formula:



-24-


where R is a hydrogen atom or a t-butyl or benzyl radical; R¹ is a hydrogen atom or a C₁₋₄ lower alkyl radical; R² is a hydrogen atom or a methyl or ethyl radical; and X and Y are independently hydrogen atoms or C₁₋₄ lower alkyl, hydroxy or C₁₋₄ lower alkoxy groups; or a pharmaceutically acceptable salt thereof.

3. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to Claim 2 and having the following general formula:



where R² is a hydrogen atom or a methyl or ethyl radical; or a pharmaceutically acceptable salt thereof.

4. A substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to Claim 2 and having the following general formula:



where R² is a hydrogen atom or a methyl or ethyl radical; or a pharmaceutically acceptable salt thereof.

5. A compound according to Claim 2, which is 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate (S,S,S); or 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxopropyl]-

1,2,3,4-tetrahydro-3-isoquinoline-carboxylic acid, phenylmethyl ester, maleate (S,S,S).

6. The compound according to Claim 2, which is 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinoline-carboxylic acid, 1,1-dimethylethyl ester (S,S,S).

7. A compound according to Claim 3, which is 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinoline-carboxylic acid, hydrochloride, hydrate (S,S,S).

8. A compound according to Claim 3, which is 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinoline-carboxylic acid, hydrochloride (S,S,S).

9. A compound according to Claim 3, which is 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethyl-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).


10. A compound according to Claim 4, which is 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).

11. A compound according to Claim 4, which is 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride (S,S,S).


12. A compound according to Claim 4, which is 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hemihydrate (S,S,S).

13. A process for producing a substituted acyl derivative of 1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid according to formula I in Claim 1 or a pharmaceutically acceptable salt thereof, which process comprises peptide coupling a suitably substituted 1,2,3,4-tetrahydro-3-isoquinoline carboxylate of the following general formula:

-26-



with an N-substituted amino acid of the following general formula:




where R^1 , R^2 , Ar, X, Y, and m are as defined in Claim 1 and R^3 is a suitably blocked carboxylic acid group; and, when desired, removing the blocking moiety of the carboxylic acid group R^3 ; and, where appropriate, converting the product to a pharmaceutically acceptable salt thereof.


14. A pharmaceutical composition comprising a substituted acyl derivative of a 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to formula I in Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

CLAIMS for Austria alone:-

1. A process for producing a substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:-




where R is a hydrogen atom or a lower alkyl or aralkyl radical; R^1 is a hydrogen atom or a lower alkyl or benzyl radical; R^2 is a hydrogen atom or a lower alkyl radical; Ar is a phenyl radical or a substituted phenyl radical having 1 or 2 substituents selected from fluorine, chlorine and bromine atoms and lower alkyl, lower alkoxy, hydroxy and amino radicals; X and Y are independently hydrogen atoms or lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphanyl, lower alkylsulphonyl or hydroxy radicals, or X and Y together constitute methylenedioxy; and m is 0,1,2 or 3; wherein lower alkyl and lower alkoxy radicals contain from 1 to 4 carbon atoms in a straight chain or branched chain; or a pharmaceutically acceptable salt of the compound of formula I: which process comprises peptide coupling a suitably substituted 1,2,3,4-tetrahydro-3-isoquinoline carboxylate of the following general formula:-




-28-

with an N-substituted amino acid of the following general formula:-




where R^1 , R^2 , Ar, X, Y and m are as defined above and R^3 is a suitably blocked carboxylic acid group; and, when desired, removing the blocking moiety of the carboxylic acid group R^3 ; and where appropriate converting the product into a pharmaceutically acceptable salt thereof.

2. A process according to Claim 1 which is for producing a substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:-




where R is a hydrogen atom or a t-butyl or benzyl radical; R^1 is a hydrogen atom or a lower alkyl radical; R^2 is a hydrogen atom or a methyl or ethyl radical; and X and Y are independently hydrogen atoms or lower alkyl, hydroxy or lower alkoxy radicals; or a pharmaceutically acceptable salt thereof.

3. A process according to Claim 1 which is for producing a substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:-



where R^2 is a hydrogen atom or a methyl or ethyl radical; or a pharmaceutically acceptable salt thereof.

4. A process according to Claim 1 which is for producing a substituted acyl derivative of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid having the following general formula:-



where R^2 is a hydrogen atom or a methyl or ethyl radical; or a pharmaceutically acceptable salt thereof.

5. A process according to Claim 2 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate (S,S,S).

6. A process according to Claim 2 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, phenylmethyl ester, maleate (S,S,S).

7. A process according to Claim 2 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 1,1-dimethylethyl ester, (S,S,S).

8. A process according to Claim 3 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).

9. A process according to Claim 3 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride (S,S,S).

10. A process according to Claim 3 which is for producing 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).

11. A process according to Claim 4 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hydrate (S,S,S).

12. A process according to Claim 4 which is for producing 2-[2-[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride (S,S,S).

13. A process according to Claim 4 which is for producing 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, hydrochloride, hemihydrate (S,S,S).

14. A process for producing a pharmaceutical composition comprising a substituted acyl derivative of a 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid according to formula I in Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; which process comprises incorporating the compound of Claim 1 in a suitable carrier.




European Patent
Office

EUROPEAN SEARCH REPORT

0049605

Application number

EP 81 30 4541

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	<u>FR - A - 2 448 533</u> (MORTON-NORWICH) * claims * ---	1-4, 14	C 07 D 217/26 C 07 C 103/52 A 61 K 31/47
	<u>EP - A - 0 012 845</u> (TANABE SEIYAKU Co. Ltd.) * pages 1-4 * ---	1, 2, 4, 14	
P	<u>FR - A - 2 456 733</u> (MORTON-NORWICH) * claims * ---	1-4, 14	
P	<u>EP - A - 0 018 104</u> (TAKEDA YAKUKI KOGYO K.K.) * pages 1-4 * ---	1-4, 14	TECHNICAL FIELDS SEARCHED (Int. Cl. 2) C 07 D 217/26 C 07 C 103/52 A 61 K 31/47
P	<u>EP - A - 0 018 549</u> (TANABE SEIYAKU Co. Ltd.) * pages 1-4 * ---	1-4, 14	
P	<u>US - A - 4 251 444</u> (FREED et al.) * columns 1 and 2 * ---	1-4, 14	
P	<u>EP - A - 0 031 741</u> (SCIENCE UNION et Cie.) * claims * ---	1-4, 14	CATEGORY OF CITED DOCUMENTS X: particularly relevant A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: conflicting application D: document cited in the application L: citation for other reasons
P	<u>EP - A - 0 024 852</u> (AMERICAN HOME PROD. Co.) * page 2; claims * -----	1-4, 14	
 The present search report has been drawn up for all claims			&: member of the same patent family, corresponding document
Place of search		Date of completion of the search	Examiner
The Hague		08.12.1981	BRIGHENTI